<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851720</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00071159</org_study_id>
    <nct_id>NCT01851720</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage</brief_title>
  <official_title>Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      Headaches associated with subarachnoid hemorrhage (SAH) cause severe pain. Headache
      management is complex, requiring a balance between pain control and preservation of
      neurological assessment. Sufficient pain control can be achieved with narcotics, however,
      these carry numerous undesirable side effects. Most critically, all narcotics can result in
      respiratory depression and sedation. For patients who present without neurological defects
      but debilitating pain, management is particularly challenging. The sedative effect of
      narcotics confounds the management of these patients by interfering with the neurological
      examination. Pain management is also a significant concern for patient's families as they
      observe suffering without full understanding of the importance of preserved mental status. In
      order to control the pain associated with SAH headaches, the use of narcotics is often
      required despite the risks. This standard therapy involves an IV bolus dose delivered by the
      provider regularly as needed for pain control. A common approach to reduce pain in other
      patient populations, including acute pain relief following major spine surgery, is patient
      controlled analgesia (PCA). With the PCA method, patients deliver low doses of narcotics
      through a pain pump with preset maximal doses and frequency of delivery. We hypothesize that
      this approach to pain relief for SAH headaches will result in lower pain scores, greater
      patient and family satisfaction scores, and increased patient safety with lower narcotic
      doses minimally interfering with neurological assessment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion criteria were too strict and therefore we were not able to recruit more patients.
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 15, 2014</completion_date>
  <primary_completion_date type="Actual">September 15, 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Pain Following Sub-Arachnoid Hemorrhage (SAH) is the Primary Outcome Variable and Will be Assessed Using the Numeric Rating Scale (NRS).</measure>
    <time_frame>4 days</time_frame>
    <description>Pain score 0-10. 0 represented no pain and 10 worst pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Headaches Associated With Subarachnoid Hemorrhage (SAH)</condition>
  <arm_group>
    <arm_group_label>Control group / Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
(Bolus dose can be titrated up in 25 mcg increments if necessary)
Maximum dose of 100 mcg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose IV fentanyl PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initially: 10 mcg demand dose every 12 minutes
No initial bolus and no continuous infusion
Demand dose increased 10 mcg every 12 minutes if necessary
Maximum dose of 100 mcg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose fentanyl PCA</intervention_name>
    <arm_group_label>Low dose IV fentanyl PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard IV fentanyl bolus</intervention_name>
    <arm_group_label>Control group / Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18-75

          -  Glasgow Coma Scale (GCS) 13 or greater

          -  Hunt and Hess grade I, II conditions

          -  Admitted within 2 days of initial SAH event &gt;6/10 pain on presentation

        Exclusion Criteria:

          -  Aphasia

          -  Head trauma within the past 30 days

          -  Need for craniotomy

          -  h/o obstructive sleep apnea or respiratory disease

          -  h/o opioid tolerance

          -  evidence of vasospasm

          -  h/o liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <results_first_submitted>April 24, 2017</results_first_submitted>
  <results_first_submitted_qc>June 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2017</results_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group / Standard of Care</title>
          <description>IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
(Bolus dose can be titrated up in 25 mcg increments if necessary)
Maximum dose of 100 mcg/hr
Standard IV fentanyl bolus</description>
        </group>
        <group group_id="P2">
          <title>Low Dose IV Fentanyl Patient Controlled Analgesia (PCA)</title>
          <description>Initially: 10 mcg demand dose every 12 minutes
No initial bolus and no continuous infusion
Demand dose increased 10 mcg every 12 minutes if necessary
Maximum dose of 100 mcg/hr
Low dose fentanyl PCA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group / Standard of Care</title>
          <description>IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
(Bolus dose can be titrated up in 25 mcg increments if necessary)
Maximum dose of 100 mcg/hr
Standard IV fentanyl bolus</description>
        </group>
        <group group_id="B2">
          <title>Low Dose IV Fentanyl PCA</title>
          <description>Initially: 10 mcg demand dose every 12 minutes
No initial bolus and no continuous infusion
Demand dose increased 10 mcg every 12 minutes if necessary
Maximum dose of 100 mcg/hr
Low dose fentanyl PCA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Pain Following Sub-Arachnoid Hemorrhage (SAH) is the Primary Outcome Variable and Will be Assessed Using the Numeric Rating Scale (NRS).</title>
        <description>Pain score 0-10. 0 represented no pain and 10 worst pain</description>
        <time_frame>4 days</time_frame>
        <population>Though one subject in the PCA arm completed enrollment, we had insufficient data to perform any comparative analysis. We do no intend to summarize the patient's results.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group / Standard of Care</title>
            <description>IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
(Bolus dose can be titrated up in 25 mcg increments if necessary)
Maximum dose of 100 mcg/hr
Standard IV fentanyl bolus</description>
          </group>
          <group group_id="O2">
            <title>Low Dose IV Fentanyl PCA</title>
            <description>Initially: 10 mcg demand dose every 12 minutes
No initial bolus and no continuous infusion
Demand dose increased 10 mcg every 12 minutes if necessary
Maximum dose of 100 mcg/hr
Low dose fentanyl PCA</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Pain Following Sub-Arachnoid Hemorrhage (SAH) is the Primary Outcome Variable and Will be Assessed Using the Numeric Rating Scale (NRS).</title>
          <description>Pain score 0-10. 0 represented no pain and 10 worst pain</description>
          <population>Though one subject in the PCA arm completed enrollment, we had insufficient data to perform any comparative analysis. We do no intend to summarize the patient's results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group / Standard of Care</title>
          <description>IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
(Bolus dose can be titrated up in 25 mcg increments if necessary)
Maximum dose of 100 mcg/hr
Standard IV fentanyl bolus</description>
        </group>
        <group group_id="E2">
          <title>Low Dose IV Fentanyl PCA</title>
          <description>Initially: 10 mcg demand dose every 12 minutes
No initial bolus and no continuous infusion
Demand dose increased 10 mcg every 12 minutes if necessary
Maximum dose of 100 mcg/hr
Low dose fentanyl PCA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alex Coon</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>410-955-2438</phone>
      <email>acoon2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

